Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Goodwill & Intangibles (2025)

NRX Pharmaceuticals (NRXP) has disclosed Goodwill & Intangibles for 1 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Goodwill & Intangibles changed N/A to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.7 million for FY2025, N/A changed from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $2.7 million at NRX Pharmaceuticals, up from $2.4 million in the prior quarter.
  • The five-year high for Goodwill & Intangibles was $2.7 million in Q4 2025, with the low at $2.4 million in Q3 2025.